

ABSTRACT OF THE DISCLOSURE

5 An analgesic benefit is realized by continuously  
supplying a peptide *in vivo* that activates an opioid  
receptor or that interferes with the binding of substance  
P to its receptors. The long-term, continuous provision  
of such a peptide can be accomplished by (a) transducing  
myogenic cells with DNA expressing the peptide and  
10 (b) administering the transduced myogenic cells to a  
patient, such that the cells continuously produce the  
peptide.

09085344-110801